405 related articles for article (PubMed ID: 20524813)
61. Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone.
Lai ME; Grady RW; Vacquer S; Pepe A; Carta MP; Bina P; Sau F; Cianciulli P; Maggio A; Galanello R; Farci P
Blood Cells Mol Dis; 2010 Aug; 45(2):136-9. PubMed ID: 20678715
[TBL] [Abstract][Full Text] [Related]
62. Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients.
Wang CH; Wu KH; Tsai FJ; Peng CT; Tsai CH
Hemoglobin; 2006; 30(2):257-62. PubMed ID: 16798651
[TBL] [Abstract][Full Text] [Related]
63. Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients.
Wu SF; Peng CT; Wu KH; Tsai CH
Hemoglobin; 2006; 30(2):215-8. PubMed ID: 16798646
[TBL] [Abstract][Full Text] [Related]
64. Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil.
Wood JC; Otto-Duessel M; Gonzalez I; Aguilar MI; Shimada H; Nick H; Nelson M; Moats R
Transl Res; 2006 Nov; 148(5):272-80. PubMed ID: 17145573
[TBL] [Abstract][Full Text] [Related]
65. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.
Ha SY; Chik KW; Ling SC; Lee AC; Luk CW; Lam CW; Ng IO; Chan GC
Hemoglobin; 2006; 30(2):263-74. PubMed ID: 16798652
[TBL] [Abstract][Full Text] [Related]
66. Deferasirox for transfusion-related iron overload: a clinical review.
Lindsey WT; Olin BR
Clin Ther; 2007 Oct; 29(10):2154-66. PubMed ID: 18042472
[TBL] [Abstract][Full Text] [Related]
67. Deferiprone: New insight.
Piga A; Roggero S; Vinciguerra T; Sacchetti L; Gallo V; Longo F
Ann N Y Acad Sci; 2005; 1054():169-74. PubMed ID: 16339662
[TBL] [Abstract][Full Text] [Related]
68. Emerging Roles of the Iron Chelators in Inflammation.
Di Paola A; Tortora C; Argenziano M; Marrapodi MM; Rossi F
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887336
[TBL] [Abstract][Full Text] [Related]
69. Iron overload disorders: treatment options for patients refractory to or intolerant of phlebotomy.
Bring P; Partovi N; Ford JA; Yoshida EM
Pharmacotherapy; 2008 Mar; 28(3):331-42. PubMed ID: 18294113
[TBL] [Abstract][Full Text] [Related]
70. Iron-chelating therapy with the new oral agent ICL670 (Exjade).
Cappellini MD
Best Pract Res Clin Haematol; 2005 Jun; 18(2):289-98. PubMed ID: 15737891
[TBL] [Abstract][Full Text] [Related]
71. Comparative study of the protective effect between deferoxamine and deferiprone on chronic iron overload induced cardiotoxicity in rats.
Emara AM; El Kelany RS; Moustafa KA
Hum Exp Toxicol; 2006 Jul; 25(7):375-85. PubMed ID: 16898166
[TBL] [Abstract][Full Text] [Related]
72. Synergistic intracellular iron chelation combinations: mechanisms and conditions for optimizing iron mobilization.
Vlachodimitropoulou Koumoutsea E; Garbowski M; Porter J
Br J Haematol; 2015 Sep; 170(6):874-83. PubMed ID: 26033030
[TBL] [Abstract][Full Text] [Related]
73. Deferasirox shows in vitro and in vivo antileukemic effects on murine leukemic cell lines regardless of iron status.
Lee DH; Jang PS; Chung NG; Cho B; Jeong DC; Kim HK
Exp Hematol; 2013 Jun; 41(6):539-46. PubMed ID: 23415674
[TBL] [Abstract][Full Text] [Related]
74. The proceedings of the 19Th international conference on chelation held in London, United Kingdom: major changes in iron chelation therapy in the last 25 years using deferiprone (L1) has resulted in the complete treatment of iron overload.
Kontoghiorghes GJ
Hemoglobin; 2011; 35(3):181-5. PubMed ID: 21599430
[TBL] [Abstract][Full Text] [Related]
75. Iron chelation in thalassemia: time to reconsider our comfort zones.
Berdoukas V; Farmaki K; Wood JC; Coates T
Expert Rev Hematol; 2011 Feb; 4(1):17-26. PubMed ID: 21322775
[TBL] [Abstract][Full Text] [Related]
76. Ability of deferasirox to bind iron during measurement of iron.
Lebitasy M; Ampe E; Hecq JD; Karmani L; Nick H; Galanti L
Clin Chem Lab Med; 2010 Mar; 48(3):427-9. PubMed ID: 20170398
[No Abstract] [Full Text] [Related]
77. Transport of iron chelators and chelates across MDCK cell monolayers: implications for iron excretion during chelation therapy.
Huang XP; Thiessen JJ; Spino M; Templeton DM
Int J Hematol; 2010 Apr; 91(3):401-12. PubMed ID: 20213118
[TBL] [Abstract][Full Text] [Related]
78. The effects of deferiprone and deferasirox on the structure and function of beta-thalassemia hemoglobin.
Moosavi-Movahedi AA; Mousavy SJ; Divsalar A; Babaahmadi A; Karimian K; Shafiee A; Kamarie M; Poursasan N; Farzami B; Riazi GH; Hakimelahi GH; Tsai FY; Ahmad F; Amani M; Saboury AA
J Biomol Struct Dyn; 2009 Dec; 27(3):319-39. PubMed ID: 19795915
[TBL] [Abstract][Full Text] [Related]
79. Iron: a target for the management of Kaposi's sarcoma?
Simonart T
BMC Cancer; 2004 Jan; 4():1. PubMed ID: 14725718
[TBL] [Abstract][Full Text] [Related]
80. Iron chelators for thalassaemia.
Hershko C; Konijn AM; Link G
Br J Haematol; 1998 Jun; 101(3):399-406. PubMed ID: 9633877
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
